As a board-certified emergency medicine physician with 15+ years managing acute vision loss in ERs, sports events like Tucson rodeo and MMA ringside, and now overseeing Pure IV protocols, I've triaged countless sudden vision cases. NAION is sudden, painless unilateral vision loss from optic nerve ischemia, often altitudinal field defect on waking; exam shows swollen disc without hemorrhage. Observational data like the 2024 JAMA Ophthalmology study links semaglutide (Ozempic/Wegovy) to 4x higher NAION risk in diabetics and 7x in obese patients, strongest at higher doses; vascular risks (HTN, sleep apnea) amplify concern, but no causality proven. Counsel GLP-1 users: seek ER for any sudden vision blur/dark spot; we prioritize fundoscopy, OCT, urgent neuro-ophthalmology--I've stabilized similar post-concussion cases before transfer.
Optometrist here, part of the inaugural Doctor of Optometry cohort from UWA with therapeutic qualifications -- meaning I diagnose and manage ocular disease, not just refract. I also do outreach work in remote WA where GLP-1 prescribing is rising but follow-up care is almost nonexistent, which makes early recognition even more critical. From my clinical perspective, the most underappreciated piece is that NAION mimics other optic nerve presentations we routinely screen for -- glaucomatous optic neuropathy, for instance. In practice, I've had patients with borderline optic nerve head morphology on OCT where the differential suddenly got more complex once I learned they were on semaglutide. Structural imaging over time is what separates these diagnoses. The patient risk profile matters enormously here. High myopia, which we manage aggressively at our clinic, is already associated with optic nerve vulnerability and structural changes from axial elongation. A highly myopic patient on a GLP-1 agent, especially with concurrent sleep apnea or hypertension, stacks risk factors in a way that warrants a much shorter monitoring interval than standard care suggests. The counselling gap is real -- most patients on these medications have never been told their optometrist needs to know. I now ask about GLP-1 use at every new patient exam and document baseline optic nerve imaging specifically because if something changes, I need that reference point before symptoms appear.
As a bariatric medicine specialist, I routinely prescribe GLP-1 receptor agonists to patients who have obesity. I have seen the changes that the weight loss and cardiometabolic benefits of these medications provide for a lot of patients; changes that are life changing for many patients from a personal and professional perspective. My role is to contextualize novel safety signals such as nonarteritic anterior ischemic optic neuropathy. The evidence is still in the early days but any changes to a patient's vision should always be treated as an emergency. Many of our patients with obesity have diabetes, hypertension, and/or sleep apnea which already increase vascular risk, so it is vital that clear counseling is provided. I preach caution without panic, and I want my patients to have these therapies, but in the certainty of knowing which symptoms require immediate evaluation. I attempt to be as transparent as I can and answer any questions when patients ask me about such headlines. My role is to offer balanced counselling and promote early detection so that patients are rest assured that their treatment is being monitored extremely closely.